FCRL6: A Potential Drug Target and Biomarker (G343413)

Target Name: FCRL6

NCBI ID: G343413

FCRL6

FCRL6: A Potential Drug Target and Biomarker

FCRL6, also known as fc receptor homolog 6, is a gene that encodes a protein located on the surface of certain cells in the body. The protein produced by this gene has been shown to interact with various types of receptors, including the type of receptor found in cancer cells. This interaction between the protein and the receptor has led to the potential for FCRL6 to be a drug target or biomarker in cancer treatment.

FCRL6 is a member of the FCRL family of proteins, which are known for their role in cell signaling. The FCRL6 protein is composed of 159 amino acid residues and has a calculated molecular weight of 19.4 kDa. It is localized to the endoplasmic reticulum and can be expressed in various cell types, including neurons, endothelial cells, and cancer cells.

One of the most significant functions of FCRL6 is its interaction with receptors. The majority of theFCRL6 protein is accounted for by the N-terminus, which is known as the N-terminal transmembrane domain. This domain is responsible for the protein's ability to interact with various types of receptors, including those found in cancer cells.

FCRL6 has been shown to interact with several different types of receptors, including the EGFR receptor, which is a well-known receptor found in many types of cancer. The EGFR receptor is involved in cell signaling and is a potential drug target for many types of cancer.

FCRL6 has also been shown to interact with the PDGF receptor, which is another type of receptor that is involved in cell signaling. The PDGF receptor is involved in the regulation of cell growth, differentiation, and survival, and is a potential drug target for many types of cancer.

In addition to its interaction with the EGFR and PDGF receptors, FCRL6 has also been shown to interact with several other types of receptors, including the FGFR receptor, which is involved in cell signaling and is found in many types of cancer.

FCRL6 has been shown to interact with the FGFR receptor in a similar way that the EGFR receptor does. This interaction between the protein and the receptor has led to the potential for FCRL6 to be a drug target for cancer.

The potential for FCRL6 to be a drug target is further supported by its association with cancer. Many studies have shown that FCRL6 is expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, several studies have shown that FCRL6 has been overexpressed in various types of cancer, which could indicate that it is involved in the development and progression of these diseases.

In addition to its potential as a drug target, FCRL6 may also be a useful biomarker for cancer. The expression of FCRL6 has been shown to be associated with the development and progression of cancer, and may be a useful indicator of disease severity in certain types of cancer.

The potential for FCRL6 to be a drug target or biomarker for cancer makes it an important area of research for scientists. Further studies are needed to fully understand the role of FCRL6 in cell signaling and its potential as a drug or biomarker for cancer.

In conclusion, FCRL6 is a gene that encodes a protein that has been shown to interact with various types of receptors, including the EGFR and PDGF receptors. Its interaction with these receptors has led to the potential for FCRL6 to be a drug target or biomarker in cancer treatment. Further studies are needed to fully understand the role of FCRL6 in cell signaling and its potential as a drug or biomarker for cancer.

Protein Name: Fc Receptor Like 6

Functions: Acts as a MHC class II receptor (PubMed:20519654). When stimulated on its own, does not play a role in cytokine production or the release of cytotoxic granules by NK cells and cytotoxic CD8(+) T cells (PubMed:17213291, PubMed:18991291). Does not act as an Fc receptor (PubMed:18991291)

The "FCRL6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCRL6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets